Meanwhile, regulars recently demanded more data before approving Neurocrine Biosciences ' indiplon sleeping pill, prompting partner Pfizer to drop its deal with Neurocrine last week.

FORBES

Meanwhile, regulars recently demanded more data before approving Neurocrine Biosciences ' (nasdaq: NBIX - news - people ) indiplon sleeping pill, prompting partner Pfizer (nyse: PFE - news - people ) to drop its deal with Neurocrine last week.

FORBES: Behavioral Therapy 1, Sleeping Pills 0